Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERY974 in advanced solid tumors
NCT02748837Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Aug 2019
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ERY974 in solid tumor, gastric cancer (GC) and esophageal carcinoma (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerated Dose and Change in tumor size. Started Aug 2016; status: completed.
02
Drugs
ERY974
03
Conditions
solid tumorgastric cancer (GC)esophageal carcinoma
Beyond the preview
Go deeper on NCT02748837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748837.